Guide · stopping

What happens when you stop

Every price on this site is a monthly price, and the trials are clear about what a last month looks like. Weight comes back at about 0.8 kg a month on semaglutide or tirzepatide, and the cardiometabolic gains go with it. This is the number to decide on before the first one.

Updated 2026-08-184 sources

The number

A 2026 systematic review and meta-analysis in the BMJ pooled 37 studies, 63 intervention arms and 9,341 participants to ask what happens after weight-management medication stops. Across all such drugs the average was 0.4 kg regained per month. For semaglutide and tirzepatide specifically it was double that: 0.8 kg a month, 95% CI 0.7 to 0.9.

The authors projected weight returning to baseline within 1.7 years of stopping, and cardiometabolic markers — HbA1c, fasting glucose, cholesterol, triglycerides, blood pressure — returning within 1.4 years. Their conclusion is worth reading exactly as written: weight-management medicines produce improvements “that are attenuated soon after treatment ends, with no evidence of benefit 1.7 years after the cessation of treatment.”

The trials the number comes from

Two withdrawal studies sit underneath it, one per molecule, and both were designed to answer this question rather than stumbling on it.

Semaglutide — the STEP 1 extension

STEP 1 is the trial that produced the −14.9% headline quoted throughout this site. Its extension followed participants after treatment stopped. Those who had been on semaglutide regained 11.6 percentage points of the weight they had lost; the placebo group regained 1.9. Cardiometabolic improvements reverted alongside the weight.

Tirzepatide — SURMOUNT-4

SURMOUNT-4 put everyone on tirzepatide for 36 weeks, then randomised them either to continue or to switch to placebo. Those who continued kept losing, reaching a mean 26% total weight reduction from study entry. Those switched to placebo regained about 14%. A later post hoc analysis found 82.5% of participants regained at least a quarter of their lost weight within a year of withdrawal, with most also showing reversal of their cardiometabolic gains.

Withdrawal findings at a glance
Study	Design	Finding on stopping
STEP 1 extension	Follow-up after semaglutide 2.4 mg	Regained 11.6 percentage points of lost weight, vs 1.9 on placebo
SURMOUNT-4	36 weeks tirzepatide, then continue or placebo	Placebo arm regained ~14%; continuing arm reached 26% total loss
SURMOUNT-4 post hoc	One year after withdrawal	82.5% regained ≥25% of the weight they had lost
BMJ 2026 meta-analysis	37 studies, 9,341 participants	0.8 kg/month on semaglutide or tirzepatide; baseline within 1.7 years

The consistent finding across all four is that the drugs work while taken and stop working when stopped. That is unremarkable for a chronic-disease medicine and would surprise nobody about blood-pressure tablets. It surprises people here because of how these products are marketed.

What this does not mean

It does not mean the treatment failed, or that the weight loss was fake. Nor does it mean regain is universal — the meta-analysis reports an average, and averages contain people who regained everything and people who regained very little. Separate real-world work has found a meaningful minority maintaining their loss a year after stopping.

It also does not mean stopping is never right. Side effects, cost, pregnancy plans and simple preference are all legitimate reasons, and none of them is improved by staying on a drug you do not want. What the evidence argues against is only one specific plan: taking a GLP-1 for a fixed short course on the assumption that the result will hold by itself.

How to use this when picking a provider

Price the maintenance dose, not the starter dose. Several services on this site advertise a figure that applies only while you titrate — the Wegovy pill at $149 and Sam’s Club at $299 are both starter-dose prices.
Prefer a provider you can leave and rejoin cheaply over one that locks you in. Prepaying a year buys a discount on a drug whose supply may be enjoined or whose legal basis may change.
Ask what happens to your prescription if you pause. A service that treats a gap as a fresh start, with new consultation fees, is more expensive than its monthly price suggests.
If you are on Medicare, check the Bridge before anything else — $50 a month is the difference between indefinite and unaffordable for most budgets.
Treat any provider marketing a fixed-length “programme” with a defined end as making a claim the trials do not support.

Questions

How fast will I regain weight if I stop?

The 2026 BMJ meta-analysis found an average of 0.8 kg a month for semaglutide and tirzepatide specifically, against 0.4 kg across weight-management drugs generally, and projected a return to baseline within about 1.7 years. That is an average across 9,341 participants; individuals vary considerably.

Do the health benefits go too?

On this evidence, yes, and slightly faster than the weight. The same analysis projected HbA1c, fasting glucose, cholesterol, triglycerides and blood pressure returning to baseline within 1.4 years, and concluded there was “no evidence of benefit 1.7 years after the cessation of treatment.”

Does that mean I have to take it forever?

It means the results last as long as the treatment does, which is how most chronic-disease medicines work. Whether to continue indefinitely is a decision for you and your prescriber, weighing cost, side effects and your own goals. What the evidence rules out is planning a short fixed course and expecting the loss to hold on its own.

Did anyone keep the weight off?

Yes. These are averages, and the distribution matters — the SURMOUNT-4 post hoc found 82.5% regained at least a quarter of their lost weight within a year, which also means some did not. Separate real-world analyses have found a portion of patients maintaining their loss a year after stopping.

How should this change which provider I pick?

Price the dose you will be on in two years rather than the one you start on, and favour flexibility over lock-in. A sustainable monthly cost matters more than a low first month, and a prepaid year is a poor fit for a drug whose supply is being litigated.

Sources

Everything on this page traces to one of the links below, retrieved on the date shown. Prices and programme terms in this market change without notice — confirm against the provider before you buy.